Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Testing Cooperative's Hematologic Neoplasms, Solid Tumor Tests Receive NY State Approval, Medicare Coverage

NEW YORK – Genomic Testing Cooperative announced on Wednesday that the New York State Clinical Evaluation Program has approved its next-generation sequencing profiling tests for hematologic neoplasms and solid tumors.

The approved tests are the GTC Hematology Profile for 177 genes; GTC Hematology Fusion/Expression for 1,408 genes; GTC Hematology PLUS for 177 DNA and 1,408 RNA; GTC Liquid Biopsy, Hematology Profile for 177 genes; GTC Solid Tumor Profile for 434 genes; GTC Solid Tumor Profile Fusion/Expression for 1,408 genes; and GTC Solid Tumor PLUS for 434 DNA and 1,408 RNA.

The tests are also covered by Medicare Administrative Contractor Palmetto GBA, Irvine, California-based GTC said in a statement, adding they are designed to comprehensively evaluate "clinically relevant molecular abnormalities and biomarkers." The tests can be performed on small samples, including needle aspiration samples, and rely on artificial intelligence to analyze sequencing runs, curate data, and interpret results.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.